Skip to main content

rivaroxaban (Xarelto®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Medicine details

Medicine name rivaroxaban (Xarelto®)
Formulation film-coated tablet
Reference number 559
Indication

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack

Company Bayer Healthcare Pharmaceuticals
BNF chapter Cardiovascular system
Assessment type N/A
Status Excluded due to NICE appraisal
Date of issue 25/11/2011
NICE guidance

TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Follow AWTTC: